{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:57:46Z","timestamp":1790643466524,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumor Electric Field Therapy (TEFT) disrupts mitosis in glioblastoma (GBM), but responses vary markedly among patients. In a retrospective cohort of TEFT-treated GBM,\n                    <jats:italic>EGFR<\/jats:italic>\n                    variant III (EGFRvIII) alteration is associated with shorter progression-free survival, prompting us to investigate a genotype-linked resistance mechanism. TEFT triggers a broadly shared bioenergetic stress response marked by activation of the AMPK-PPAR\u03b1-CPT1A axis, whereas EGFRvIII primes\n                    <jats:italic>IDO1<\/jats:italic>\n                    transcription through NF-\u03baB. CPT1A further stabilizes IDO1 by promoting succinylation at lysine 377 through non-canonical LSTase-related activity, thereby limiting TRIM21-dependent ubiquitination and proteasomal degradation. Accumulated IDO1 increases kynurenine production and activates AhR, which upregulates\n                    <jats:italic>DCLK1<\/jats:italic>\n                    and\n                    <jats:italic>ARHGEF2<\/jats:italic>\n                    to preserve spindle organization and microtubule dynamics during electric-field exposure. Thus, EGFRvIII converts a general stress-adaptation pathway into a selective cytoprotective program. Genetic or pharmacological disruption of this pathway restores TEFT sensitivity in established and patient-derived GBM cells, organoids, and orthotopic models. Osimertinib suppresses the EGFRvIII-NF-\u03baB-IDO1 arm and enhances TEFT efficacy, while exploratory clinical cases provide preliminary mechanism-informed support for the combination in recurrent EGFR-driven GBM. These findings define a genotype\u2013field convergence mechanism linking metabolic adaptation to mitotic protection and support prospective evaluation of osimertinib plus TEFT.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-77927-w","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:14:26Z","timestamp":1790187266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CPT1A-mediated IDO1 succinylation shapes EGFRvIII-driven resistance to tumor electric field therapy in glioblastoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-0944","authenticated-orcid":false,"given":"Bowen","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huize","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-7550","authenticated-orcid":false,"given":"Yanhua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-9330","authenticated-orcid":false,"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"77927_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff, L. R. & Mellinghoff, I. K. Glioblastoma and other primary brain malignancies in adults: a review. JAMA 329, 574\u2013587 (2023).","journal-title":"JAMA"},{"key":"77927_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jama.2023.8587","volume":"330","author":"AP Wang","year":"2023","unstructured":"Wang, A. P. A review of glioblastoma and other primary brain malignancies. JAMA 330, 188\u2013189 (2023).","journal-title":"JAMA"},{"key":"77927_CR3","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","volume":"402","author":"MJ van den Bent","year":"2023","unstructured":"van den Bent, M. J. et al. Primary brain tumours in adults. Lancet 402, 1564\u20131579 (2023).","journal-title":"Lancet"},{"key":"77927_CR4","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen, P. Y. et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J. Clin. Oncol. 41, 5187\u20135199 (2023).","journal-title":"J. Clin. Oncol."},{"key":"77927_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","volume":"187","author":"R Mathur","year":"2024","unstructured":"Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446\u2013463.e16 (2024).","journal-title":"Cell"},{"key":"77927_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 25, 339\u2013350 (2023).","journal-title":"Neuro Oncol."},{"key":"77927_CR7","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/neuonc\/noae060","volume":"26","author":"A \u00c1lvarez-V\u00e1zquez","year":"2024","unstructured":"\u00c1lvarez-V\u00e1zquez, A. et al. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models. Neuro Oncol. 26, 1230\u20131246 (2024).","journal-title":"Neuro Oncol."},{"key":"77927_CR8","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/neuonc\/noac204","volume":"24","author":"B Lin","year":"2022","unstructured":"Lin, B. et al. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 24, 2035\u20132062 (2022).","journal-title":"Neuro Oncol."},{"key":"77927_CR9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/cac2.12502","volume":"43","author":"X Cui","year":"2023","unstructured":"Cui, X. et al. Blockage of EGFR\/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Commun. 43, 1326\u20131353 (2023).","journal-title":"Cancer Commun."},{"key":"77927_CR10","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1080\/15548627.2020.1816343","volume":"17","author":"I Compter","year":"2020","unstructured":"Compter, I. et al. Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy 17, 2604\u20132612 (2020).","journal-title":"Autophagy"},{"key":"77927_CR11","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","volume":"82","author":"JC Moser","year":"2022","unstructured":"Moser, J. C. et al. The mechanisms of action of tumor treating fields. Cancer Res. 82, 3650\u20133658 (2022).","journal-title":"Cancer Res."},{"key":"77927_CR12","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp, R. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314, 2535\u20132543 (2015).","journal-title":"JAMA"},{"key":"77927_CR13","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"77927_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn, M. J. B. et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 495\u2013504 (2018).","journal-title":"JAMA Oncol."},{"key":"77927_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/neuonc\/noae213","volume":"27","author":"MJ van den Bent","year":"2025","unstructured":"van den Bent, M. J. et al. Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1. Neuro Oncol. 27, 331\u2013337 (2025).","journal-title":"Neuro Oncol."},{"key":"77927_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14720","volume":"30","author":"J Lan","year":"2024","unstructured":"Lan, J. et al. Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma. CNS Neurosci. Ther. 30, e14720 (2024).","journal-title":"CNS Neurosci. Ther."},{"key":"77927_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/0008-5472.CAN-23-3643","volume":"85","author":"D Chen","year":"2025","unstructured":"Chen, D. et al. The EP3-ZNF488 axis promotes self-renewal of glioma stem-like cells to induce resistance to tumor treating fields. Cancer Res. 85, 360\u2013377 (2025).","journal-title":"Cancer Res."},{"key":"77927_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41420-025-02542-5","volume":"11","author":"P Deshors","year":"2025","unstructured":"Deshors, P., Kheil, Z., Ligat, L., Gouaz\u00e9-Andersson, V. & Cohen-Jonathan Moyal, E. FGFR inhibition as a new therapeutic strategy to sensitize glioblastoma stem cells to tumor treating fields. Cell Death Discov. 11, 265 (2025).","journal-title":"Cell Death Discov."},{"key":"77927_CR19","doi-asserted-by":"publisher","first-page":"vdac096","DOI":"10.1093\/noajnl\/vdac096","volume":"4","author":"M Pandey","year":"2022","unstructured":"Pandey, M. et al. Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neuro-Oncol. Adv. 4, vdac096 (2022).","journal-title":"Neuro-Oncol. Adv."},{"key":"77927_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp7603","volume":"390","author":"S Groessl","year":"2025","unstructured":"Groessl, S. et al. Acidosis orchestrates adaptations of energy metabolism in tumors. Science 390, eadp7603 (2025).","journal-title":"Science"},{"key":"77927_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41568-025-00848-1","volume":"25","author":"PK Parida","year":"2025","unstructured":"Parida, P. K. & Malladi, S. Metabolic adaptations of brain metastasis. Nat. Rev. Cancer 25, 723\u2013739 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"77927_CR22","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.ccell.2025.06.021","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. Cancer Cell 43, 1677\u20131696.e15 (2025).","journal-title":"Cancer Cell"},{"key":"77927_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33285-x","volume":"13","author":"D Shi","year":"2022","unstructured":"Shi, D. et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat. Commun. 13, 5644 (2022).","journal-title":"Nat. Commun."},{"key":"77927_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"77927_CR25","unstructured":"Humangenomics.The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648\u2013660 (2015)."},{"key":"77927_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gpb.2020.10.005","volume":"19","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteom. Bioinforma. 19, 1\u201312 (2021).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"77927_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct. Target Ther. 8, 210 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"77927_CR28","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.7150\/thno.74600","volume":"12","author":"B Li","year":"2022","unstructured":"Li, B. et al. The N6-methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2. Theranostics 12, 6363\u20136379 (2022).","journal-title":"Theranostics"},{"key":"77927_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.it.2017.07.005","volume":"38","author":"DA Rhodes","year":"2017","unstructured":"Rhodes, D. A. & Isenberg, D. A. TRIM21 and the function of antibodies inside cells. Trends Immunol. 38, 916\u2013926 (2017).","journal-title":"Trends Immunol."},{"key":"77927_CR30","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498\u20131503 (2011).","journal-title":"Nat. Med."},{"key":"77927_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.21","volume":"8","author":"Y-A Wen","year":"2017","unstructured":"Wen, Y.-A. et al. Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis. 8, e2593 (2017).","journal-title":"Cell Death Dis."},{"key":"77927_CR32","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s42255-024-01047-2","volume":"6","author":"Y Meng","year":"2024","unstructured":"Meng, Y. et al. Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance \u03b2-oxidation and tumor cell proliferation. Nat. Metab. 6, 1092\u20131107 (2024).","journal-title":"Nat. Metab."},{"key":"77927_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"77927_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-024-01772-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma, L. et al. Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal Transduct. Target Ther. 9, 64 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"77927_CR35","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1016\/j.molcel.2023.10.043","volume":"83","author":"G Zhang","year":"2023","unstructured":"Zhang, G. et al. CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. Mol. Cell 83, 4370\u20134385.e9 (2023).","journal-title":"Mol. Cell"},{"key":"77927_CR36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.celrep.2018.01.030","volume":"22","author":"K Kurmi","year":"2018","unstructured":"Kurmi, K. et al. Carnitine palmitoyltransferase 1A has a lysine succinyltransferase activity. Cell Rep. 22, 1365\u20131373 (2018).","journal-title":"Cell Rep."},{"key":"77927_CR37","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s42003-023-04993-x","volume":"6","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Carnitine palmitoyltransferase 1A promotes mitochondrial fission by enhancing MFF succinylation in ovarian cancer. Commun. Biol. 6, 618 (2023).","journal-title":"Commun. Biol."},{"key":"77927_CR38","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik, A. et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell 182, 1252\u20131270.e34 (2020).","journal-title":"Cell"},{"key":"77927_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-019-0103-4","volume":"5","author":"L Du","year":"2020","unstructured":"Du, L. et al. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct. Target Ther. 5, 10 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"77927_CR40","doi-asserted-by":"publisher","first-page":"W45","DOI":"10.1093\/nar\/gkae358","volume":"52","author":"Z Zou","year":"2024","unstructured":"Zou, Z., Ohta, T. & Oki, S. ChIP-Atlas 3.0: a data-mining suite to explore chromosome architecture together with large-scale regulome data. Nucleic Acids Res. 52, W45\u2013W53 (2024).","journal-title":"Nucleic Acids Res."},{"key":"77927_CR41","doi-asserted-by":"publisher","first-page":"D61","DOI":"10.1093\/nar\/gkw951","volume":"45","author":"I Yevshin","year":"2016","unstructured":"Yevshin, I., Sharipov, R., Valeev, T., Kel, A. & Kolpakov, F. GTRD: a database of transcription factor binding sites identified by ChIP-seq experiments. Nucleic Acids Res. 45, D61\u2013D67 (2016).","journal-title":"Nucleic Acids Res."},{"key":"77927_CR42","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/neuonc\/now182","volume":"18","author":"AF Hottinger","year":"2016","unstructured":"Hottinger, A. F., Pacheco, P. & Stupp, R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol. 18, 1338\u20131349 (2016).","journal-title":"Neuro Oncol."},{"key":"77927_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","volume":"24","author":"EJ Mun","year":"2017","unstructured":"Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D. & Von Hoff, D. D. Tumor-treating fields: a fourth modality in cancer treatment. Clin. Cancer Res. 24, 266\u2013275 (2017).","journal-title":"Clin. Cancer Res."},{"key":"77927_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neuron.2005.10.039","volume":"49","author":"T Shu","year":"2006","unstructured":"Shu, T. et al. Doublecortin-like kinase controls neurogenesis by regulating mitotic spindles and M phase progression. Neuron 49, 25\u201339 (2006).","journal-title":"Neuron"},{"key":"77927_CR45","volume":"3","author":"L Cheng","year":"2021","unstructured":"Cheng, L. et al. DCLK1 autoinhibition and activation in tumorigenesis. Innov. (Camb.) 3, 100191 (2021).","journal-title":"Innov. (Camb.)"},{"key":"77927_CR46","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1126\/science.1096896","volume":"307","author":"M Glotzer","year":"2005","unstructured":"Glotzer, M. The molecular requirements for cytokinesis. Science 307, 1735\u20131739 (2005).","journal-title":"Science"},{"key":"77927_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/cells8060568","volume":"8","author":"Z Xu","year":"2019","unstructured":"Xu, Z., Chen, Y. & Chen, Y. Spatiotemporal regulation of Rho GTPases in neuronal migration. Cells 8, 568 (2019).","journal-title":"Cells"},{"key":"77927_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/01.RES.0000200162.94463.d7","volume":"98","author":"E Tzima","year":"2006","unstructured":"Tzima, E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ. Res. 98, 176\u2013185 (2006).","journal-title":"Circ. Res."},{"key":"77927_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.ade3925","volume":"380","author":"J Zecha","year":"2023","unstructured":"Zecha, J. et al. Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. Science 380, 93\u2013101 (2023).","journal-title":"Science"},{"key":"77927_CR50","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1182\/bloodadvances.2020002539","volume":"5","author":"DCH Chan","year":"2021","unstructured":"Chan, D. C. H. et al. Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis. Blood Adv. 5, 3120\u20133133 (2021).","journal-title":"Blood Adv."},{"key":"77927_CR51","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0124","volume":"1","author":"K Tanaka","year":"2011","unstructured":"Tanaka, K. et al. Oncogenic EGFR signaling activates an mTORC2-NF-\u03baB pathway that promotes chemotherapy resistance. Cancer Discov. 1, 524\u2013538 (2011).","journal-title":"Cancer Discov."},{"key":"77927_CR52","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","volume":"27","author":"L Zhai","year":"2021","unstructured":"Zhai, L. et al. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clin. Cancer Res. 27, 6514\u20136528 (2021).","journal-title":"Clin. Cancer Res."},{"key":"77927_CR53","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-17-0120","volume":"23","author":"L Zhai","year":"2017","unstructured":"Zhai, L. et al. Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clin. Cancer Res. 23, 6650\u20136660 (2017).","journal-title":"Clin. Cancer Res."},{"key":"77927_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature14624","volume":"526","author":"S Schoors","year":"2015","unstructured":"Schoors, S. et al. Corrigendum: fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 526, 144 (2015).","journal-title":"Nature"},{"key":"77927_CR55","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.stem.2018.04.001","volume":"22","author":"MM Mihaylova","year":"2018","unstructured":"Mihaylova, M. M. et al. Fasting activates fatty acid oxidation to enhance intestinal stem cell function during homeostasis and aging. Cell Stem Cell 22, 769\u2013778.e4 (2018).","journal-title":"Cell Stem Cell"},{"key":"77927_CR56","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1158\/1541-7786.MCR-23-0049","volume":"21","author":"H Jiang","year":"2023","unstructured":"Jiang, H. et al. Mitochondrial uncoupling inhibits reductive carboxylation in cancer cells. Mol. Cancer Res. 21, 1010\u20131016 (2023).","journal-title":"Mol. Cancer Res."},{"key":"77927_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.canlet.2018.08.006","volume":"435","author":"Y Ma","year":"2018","unstructured":"Ma, Y. et al. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 435, 92\u2013100 (2018).","journal-title":"Cancer Lett."},{"key":"77927_CR58","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.molcel.2018.01.001","volume":"69","author":"X-X Li","year":"2018","unstructured":"Li, X.-X. et al. Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation. Mol. Cell 69, 480\u2013492.e7 (2018).","journal-title":"Mol. Cell"},{"key":"77927_CR59","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s13046-023-02928-2","volume":"42","author":"S Cheng","year":"2023","unstructured":"Cheng, S. et al. RGCC-mediated PLK1 activity drives breast cancer lung metastasis by phosphorylating AMPK\u03b12 to activate oxidative phosphorylation and fatty acid oxidation. J. Exp. Clin. Cancer Res 42, 342 (2023).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"77927_CR60","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell, T. C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II Trial (ECHO-202\/KEYNOTE-037). J. Clin. Oncol. 36, 3223\u20133230 (2018).","journal-title":"J. Clin. Oncol."},{"key":"77927_CR61","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083\u20131097 (2019).","journal-title":"Lancet Oncol."},{"key":"77927_CR62","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(19)30312-2","volume":"20","author":"VK Sondak","year":"2019","unstructured":"Sondak, V. K. & Khushalani, N. I. Echoes of a failure: what lessons can we learn? Lancet Oncol. 20, 1037\u20131039 (2019).","journal-title":"Lancet Oncol."},{"key":"77927_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J. Hematol. Oncol. 11, 100 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"77927_CR64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","volume":"14","author":"K Tang","year":"2021","unstructured":"Tang, K., Wu, Y.-H., Song, Y. & Yu, B. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J. Hematol. Oncol. 14, 68 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"77927_CR65","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature13684","volume":"512","author":"P Moura-Alves","year":"2014","unstructured":"Moura-Alves, P. et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature 512, 387\u2013392 (2014).","journal-title":"Nature"},{"key":"77927_CR66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2020","unstructured":"Colclough, N. et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin. Cancer Res. 27, 189\u2013201 (2020).","journal-title":"Clin. Cancer Res."},{"key":"77927_CR67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-016-0268-z","volume":"9","author":"S Wang","year":"2016","unstructured":"Wang, S., Cang, S. & Liu, D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J. Hematol. Oncol. 9, 34 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"77927_CR68","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/annonc\/mdw129","volume":"27","author":"A Yver","year":"2016","unstructured":"Yver, A. Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development. Ann. Oncol. 27, 1165\u20131170 (2016).","journal-title":"Ann. Oncol."},{"key":"77927_CR69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2016","unstructured":"Mok, T. S. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N. Engl. J. Med. 376, 629\u2013640 (2016).","journal-title":"N. Engl. J. Med."},{"key":"77927_CR70","doi-asserted-by":"publisher","first-page":"v14","DOI":"10.1093\/neuonc\/noad179.0055","volume":"25","author":"J Nahm","year":"2023","unstructured":"Nahm, J. et al. BIOM-44. Improved overall survival of recurrent glioblastoma (GBM) PATIENTS with EGFR amplification and EGFR VIII mutations treated with osimertinib: a retrospective review. Neuro Oncol. 25, v14\u2013v14 (2023).","journal-title":"Neuro Oncol."},{"key":"77927_CR71","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2019-0014","volume":"8","author":"I Makhlin","year":"2019","unstructured":"Makhlin, I. et al. Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma. CNS Oncol. 8, CNS43 (2019).","journal-title":"CNS Oncol."},{"key":"77927_CR72","doi-asserted-by":"publisher","first-page":"oyaf146","DOI":"10.1093\/oncolo\/oyaf146","volume":"30","author":"F Villanacci","year":"2025","unstructured":"Villanacci, F. et al. Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib. Oncologist 30, oyaf146 (2025).","journal-title":"Oncologist"},{"key":"77927_CR73","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc3918","volume":"15","author":"FB Furnari","year":"2015","unstructured":"Furnari, F. B., Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 15, 302\u2013310 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"77927_CR74","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","volume":"28","author":"MA Qazi","year":"2017","unstructured":"Qazi, M. A. et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann. Oncol. 28, 1448\u20131456 (2017).","journal-title":"Ann. Oncol."},{"key":"77927_CR75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu, K., Xie, F., Wang, F. & Fu, L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J. Hematol. Oncol. 15, 173 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"77927_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01307-9","volume":"20","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Mol. Cancer 20, 17 (2021).","journal-title":"Mol. Cancer"},{"key":"77927_CR77","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"77927_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/neuonc\/now247","volume":"19","author":"RL Bowman","year":"2016","unstructured":"Bowman, R. L., Wang, Q., Carro, A., Verhaak, R. G. W. & Squatrito, M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 19, 139\u2013141 (2016).","journal-title":"Neuro Oncol."},{"key":"77927_CR79","doi-asserted-by":"publisher","first-page":"qzaf072","DOI":"10.1093\/gpbjnl\/qzaf072","volume":"23","author":"S Zhang","year":"2025","unstructured":"Zhang, S. et al. The GSA family in 2025: a broadened sharing platform for multi-omics and multimodal data. Genomics Proteom. Bioinforma. 23, qzaf072 (2025).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"77927_CR80","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013D1217 (2019).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77927-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77927-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77927-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:03:31Z","timestamp":1790640211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77927-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77927"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77927-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10277"}}